Panacea Biotec Limited
NSE: PANACEABIO BSE: PANACEABIO
Prev Close
403.1
Open Price
403.1
Volume
95,716
Today Low / High
402.75 / 415.05
52 WK Low / High
200.05 / 581.9
Range
388 - 429
Prev Close
403.45
Open Price
403.5
Volume
8,236
Today Low / High
403.5 / 414.7
52 WK Low / High
200 / 581
Range
387 - 428
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 408.15 (target range: 388 - 429), reflecting a change of 5.05 (1.25279%). On the BSE, it is listed at 407.75 (target range: 387 - 428), showing a change of 4.3 (1.06581%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Panacea Biotec Limited Graph
Panacea Biotec Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Panacea Biotec Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 408.15, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 407.75 | 411.83 | 370.64 - 453.01 |
| 415.91 | 332.72 - 499.09 | ||
| 419.98 | 293.99 - 545.98 | ||
| Bearish Scenario | 407.75 | 403.67 | 363.31 - 444.04 |
| 399.60 | 319.68 - 479.51 | ||
| 395.52 | 276.86 - 514.17 |
Overview of Panacea Biotec Limited
ISIN
INE922B01023
Industry
Biotechnology
Vol.Avg
210,357
Market Cap
24,999,473,205
Last Dividend
0
Official Website
IPO Date
2002-07-01
DCF Diff
1,085.75
DCF
-541
Financial Ratios Every Investor Needs
Stock Dividend of PANACEABIO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2011-09-19 | September 19, 11 | 0.75 | 0.75 | 2011-09-20 | 2011-10-10 | 2011-05-13 |
| 2010-09-16 | September 16, 10 | 0.25 | 0.25 | 2010-09-18 | 2010-10-25 | 2010-05-07 |
| 2008-09-19 | September 19, 08 | 1 | 1 | 2008-09-23 | 2008-10-26 | 2008-06-26 |
| 2007-09-21 | September 21, 07 | 1 | 1 | 2007-09-25 | 2007-10-28 | 2007-06-14 |
| 2006-09-22 | September 22, 06 | 1 | 1 | 2006-09-26 | 2006-10-11 | 2006-05-22 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 559.09 Cr | 199.54 Cr | 359.55 Cr | 0.6431 | 0.00 Cr | 0.00 Cr | -60.72 Cr | -8.37 Cr | -1.37 | 30.74 Cr | -0.0150 |
| 2024-03-31 | 559.17 Cr | 230.13 Cr | 329.04 Cr | 0.5885 | 0.00 Cr | 29.53 Cr | -44.22 Cr | -1.17 Cr | -0.19 | 41.54 Cr | -0.0021 |
| 2023-03-31 | 459.95 Cr | 252.66 Cr | 207.29 Cr | 0.4507 | 13.91 Cr | 15.84 Cr | -105.65 Cr | -33.24 Cr | -5.43 | 56.37 Cr | -0.0723 |
| 2022-03-31 | 659.22 Cr | 317.67 Cr | 341.56 Cr | 0.5181 | 10.51 Cr | 27.67 Cr | -51.82 Cr | 1,078.32 Cr | 176.05 | 1,673.97 Cr | 1.6357 |
| 2021-03-31 | 617.65 Cr | 204.63 Cr | 413.02 Cr | 0.6687 | 12.56 Cr | 27.47 Cr | 42.73 Cr | -147.70 Cr | -24.11 | 86.52 Cr | -0.2391 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 82.13 Cr | 1,289.75 Cr | 459.13 Cr | 834.7900 Cr | 22.21 Cr | -59.92 Cr | 213.67 Cr | 636.90 Cr | 0.00 Cr | 0.00 Cr | 21.95 Cr | 366.9900 Cr |
| 2024-03-31 | 47.17 Cr | 1,240.67 Cr | 402.45 Cr | 842.0460 Cr | 20.99 Cr | -26.18 Cr | 177.94 Cr | 634.76 Cr | 0.00 Cr | 0.00 Cr | -52.96 Cr | 308.8320 Cr |
| 2023-03-31 | 39.85 Cr | 1,271.17 Cr | 431.05 Cr | 843.6030 Cr | 20.22 Cr | -19.63 Cr | 202.09 Cr | 623.34 Cr | 0.00 Cr | 32.14 Cr | -168.24 Cr | 331.8310 Cr |
| 2022-03-31 | 50.35 Cr | 1,758.87 Cr | 885.21 Cr | 876.6360 Cr | 34.16 Cr | -16.20 Cr | 212.72 Cr | 592.72 Cr | 0.00 Cr | 43.13 Cr | -417.62 Cr | 776.3670 Cr |
| 2021-03-31 | 52.08 Cr | 1,177.53 Cr | 1,409.23 Cr | -228.6930 Cr | 819.53 Cr | 767.45 Cr | 174.14 Cr | 627.89 Cr | 0.00 Cr | 2.91 Cr | -37.69 Cr | 449.0910 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -27.3700 Cr | 64.9800 Cr | -2.6600 Cr | -77.6800 Cr | 34.9600 Cr | 82.1300 Cr | -50.3100 Cr | -7.9500 Cr | 0.0000 Cr | 0.0000 Cr | -35.7400 Cr |
| 2024-03-31 | -0.1000 Cr | 10.2270 Cr | -2.8080 Cr | -77.8180 Cr | 7.3220 Cr | 47.1740 Cr | -77.7180 Cr | -1.1730 Cr | -0.2360 Cr | 0.0000 Cr | 24.1580 Cr |
| 2023-03-31 | -422.4520 Cr | 430.3300 Cr | -18.3730 Cr | -463.3980 Cr | -10.4980 Cr | 39.8520 Cr | -40.9460 Cr | 12.8000 Cr | -14.7740 Cr | 0.0000 Cr | 10.6300 Cr |
| 2022-03-31 | -108.4480 Cr | 1,282.5730 Cr | -1,175.8540 Cr | -120.9580 Cr | -1.7290 Cr | 50.3500 Cr | -12.5100 Cr | 1,448.8080 Cr | -786.0680 Cr | 0.0000 Cr | -38.5800 Cr |
| 2021-03-31 | 106.6500 Cr | -47.6790 Cr | -47.1100 Cr | 85.0010 Cr | 11.8610 Cr | 52.0790 Cr | -21.7630 Cr | -145.0300 Cr | 52.2860 Cr | 0.0000 Cr | -26.4450 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 132.53 Cr | 52.08 Cr | 80.45 Cr | 0.6070 | -35.30 Cr | -1.89 Cr | -0.31 | 9.42 Cr | -0.0143 |
| 2024-12-31 | 163.49 Cr | 62.55 Cr | 100.94 Cr | 0.6174 | -1.02 Cr | 4.52 Cr | 0.74 | 14.35 Cr | 0.0276 |
| 2024-09-30 | 147.35 Cr | 43.19 Cr | 104.16 Cr | 0.7069 | -1.68 Cr | 4.80 Cr | 0.77 | 14.42 Cr | 0.0326 |
| 2024-06-30 | 115.72 Cr | 87.95 Cr | 27.77 Cr | 0.2400 | -22.72 Cr | -15.80 Cr | -2.59 | -7.45 Cr | -0.1365 |
| 2024-03-31 | 136.46 Cr | 96.99 Cr | 39.47 Cr | 0.2892 | -14.85 Cr | -1.66 Cr | -0.23 | 7.51 Cr | -0.0122 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 82.13 Cr | 96.99 Cr | 179.12 Cr | 75.13 Cr | 213.67 Cr | 545.18 Cr | 636.90 Cr | 1,289.75 Cr | 459.13 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 177.45 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -828.92 Cr |
| 2024-09-30 | 47.67 Cr | 154.77 Cr | 202.44 Cr | 67.08 Cr | 166.82 Cr | 503.77 Cr | 630.08 Cr | 1,243.08 Cr | 414.16 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 179.84 Cr | 0.00 Cr | 0.00 Cr | 179.84 Cr | 0.00 Cr | 0.00 Cr | -838.23 Cr |
| 2024-03-31 | 47.17 Cr | 109.12 Cr | 156.29 Cr | 54.82 Cr | 177.94 Cr | 485.18 Cr | 634.76 Cr | 1,240.67 Cr | 402.45 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 4.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 4.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -15.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -1.66 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -2.20 Cr | 18.22 Cr | 0.00 Cr | 0.00 Cr | 18.22 Cr | 55.27 Cr | 37.05 Cr | 0.00 Cr | 18.22 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2003-02-03 | February 03, 03 | 10:1 |
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹359.50 | ₹480,637,120,000.00 | ₹1,022,580.00 |
| Syngene International Limited | SYNGENE | ₹667.40 | ₹267,870,930,256.00 | ₹196,956.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹192.75 | ₹256,212,590,550.00 | ₹2,776,948.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,767.60 | ₹184,919,595,120.00 | ₹188,946.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹775.35 | ₹134,496,413,397.00 | ₹242,236.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹717.05 | ₹114,212,441,050.00 | ₹143,014.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹689.55 | ₹55,496,914,740.00 | ₹82,197.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹268.15 | ₹42,041,361,450.00 | ₹62,573.00 |
| Zota Health Care Limited | ZOTA | ₹1,269.70 | ₹38,227,365,780.00 | ₹33,784.00 |
Key Executives
Gender: Not Specified
Year Born: 1975
Gender: male
Year Born: 1965
Gender: male
Year Born: 1989
Gender: Not Specified
Year Born: 1961
Gender: Not Specified
Year Born:
Gender: male
Year Born: 1973
Gender: male
Year Born:
Gender: Not Specified
Year Born: 1964
Gender: male
Year Born: 1966
Gender: male
Year Born: 1967
FAQs about Panacea Biotec Limited
The CEO is Rajesh Jain.
The current price is ₹408.15.
The range is ₹200.05-581.9.
The market capitalization is ₹2,499.95 crores.
The P/E ratio is -297.92.
The company operates in the Healthcare sector.
Overview of Panacea Biotec Limited (ISIN: INE922B01023) is a leading Biotechnology in India. With a market capitalization of ₹2,499.95 crores and an average daily volume of 210,357 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.